Monopar Enterprise Value Over E B I T D A from 2010 to 2024
| MNPR Stock | USD 0.61 0.01 1.61% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 0.29023918 | Current Value 0.3 | Quarterly Volatility 111.10817335 |
Check Monopar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Monopar main balance sheet or income statement drivers, such as Interest Expense of 23.2 K, Selling General Administrative of 2.2 M or Research Development of 5.3 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.8. Monopar financial statements analysis is a perfect complement when working with Monopar Therapeutics Valuation or Volatility modules.
Monopar | Enterprise Value Over E B I T D A |
Latest Monopar Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Monopar Therapeutics over the last few years. It is Monopar Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monopar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Monopar Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (116.83) | |
| Coefficient Of Variation | (95.10) | |
| Mean Deviation | 105.41 | |
| Median | (79.13) | |
| Standard Deviation | 111.11 | |
| Sample Variance | 12,345 | |
| Range | 230 | |
| R-Value | 0.90 | |
| Mean Square Error | 2,593 | |
| R-Squared | 0.80 | |
| Slope | 22.29 | |
| Total Sum of Squares | 172,830 |
Monopar Enterprise Value Over E B I T D A History
About Monopar Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Monopar Therapeutics income statement, its balance sheet, and the statement of cash flows. Monopar Therapeutics investors use historical funamental indicators, such as Monopar Therapeutics's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Monopar Therapeutics investors may use each financial statement separately, they are all related. The changes in Monopar Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Monopar Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Monopar Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Monopar Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 0.29 | 0.30 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Monopar Therapeutics Correlation against competitors. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Monopar Stock analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Monopar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Return On Assets (0.48) | Return On Equity (0.93) |
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.